Radionuclide Treatment Yields Responses in mCRPC.
In a phase II, single-arm prospective trial, a novel, targeted radionuclide called Lutetium-177 PSMA-617 extended survival and improved quality of life in men with metastatic, castration-resistant prostate cancer whose disease advanced despite standard therapy.